Compare Procter & Gamble Co (PG) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Tenet Healthcare Corporation — how do they compare? Procter & Gamble Co trades at $149.79 (market cap $344.87B), while Tenet Healthcare Corporation trades at $198.14 (market cap $16.93B). The key difference: Procter & Gamble Co is far larger — about 20.4× Tenet Healthcare Corporation's market cap, and Procter & Gamble Co pays a 2.94% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| PG | THC | |
|---|---|---|
Market Cap | $344.87B | $16.93B |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $244.80 |
52-Week Low | $138.10 | $148.38 |
Enterprise Value | $370.34B | $27.17B |
Dividend Yield | 2.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $149.53, up 0.26% on the day, near its consensus price target of $160.50. Recent quarters show consistent earnings beats, with Q2 2026 EPS expected at $1.41. The stock exhibits neutral technical signals with support at $147 and resistance at $150. Strong fundamentals include a 19.16% net income margin and $17.82B operating cash flow for 2025, though valuation multiples like P/E of 21.65 are premium versus peers. Recent news highlights PG's dividend reliability and supply chain enhancements.
PG offers stable growth and income, supported by 69 straight years of dividend increases and solid cash flows. Risks include premium valuation concerns and soft demand outlooks. Analyst consensus is bullish with 53.85% buy ratings, but near-term upside may be limited by economic headwinds. The stock remains a defensive pick for long-term investors seeking consistent returns.
Tenet Healthcare (THC) trades at $194.38, down 0.27% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten EPS estimates for three consecutive quarters, with a Q2 2026 report due July 24. Valuation metrics appear attractive with a P/E of 10.11 and P/S of 0.79. Revenue and net income are projected to grow in 2026, supported by expansion in outpatient care.
The outlook is positive given analyst consensus with 81% buy ratings and a $234.63 price target, implying 21% upside. Risks include potential pressure from lower patient days and high debt levels. Earnings growth and ambulatory care performance remain key catalysts for near-term momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
